Gene therapy for autoimmune disorders

Journal of Clinical Immunology

Volumn 20, Issue 5, 2000, Pages 334-346

  Evans, C H ^a   Ghivizzani, S C ^a   Oligino, T J ^b   Robbins, P D ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; Dendritic cell; Gene; Human trial; Synovium; T lymphocyte; Vector

Indexed keywords

COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOMODULATION; LUPUS VULGARIS; MULTIPLE SCLEROSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVECTOMY; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; MICE;

EID: 0033782816     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006616029205     Document Type: Review

References (105)

1. Gene therapy in autoimmune diseases
2. Gene therapy for autoimmune diseases and allograft
3. Gene therapy for rheumatic diseases
4. Gene therapy for autoimmune disease
5. Joint efforts: Tackling arthritis using gene therapy
6. Gene therapy of arthritis
7. Viral vectors for gene therapy
8. In vitro analysis of transformation potential associated with retroviral vector insertions
9. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
10. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
11. Recombinant adeno-associated virus for muscle directed gene therapy
12. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
13. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
14. The promise of nucleic acid vaccines
15. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines
16. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines
17. A targeted DNA vaccine elicits an immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis
18. Protection of rats from adjuvant arthritis by immunization with naked DNA encoding for mycobacterial heat shock protein 65
19. DNA vaccination as an anti-inflammatory strategy
20. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity
21. Treatment of murine lupus with CTLA 4Ig
22. CD28-B 7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system
23. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig
24. Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis
25. CD28-B 7 blockade prevents the development of experimental autoimmune glomerulonephritis
26. A gene therapy or purified CTLA 4IgG treatment of experimental allergic encephalomyelitis
27. CD40-CD 40 ligand interaction in autoimmune disease
28. CD 40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation
29. CD40-CD154 interaction in experimental and human disease
30. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis
31. Interleukin-1 receptor antagonist
32. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis
33. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis
34. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells
35. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1
36. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells
37. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice
38. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene
39. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis
40. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis
41. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer
42. Gene therapy of established murine collagen-induced arthritis by local and systemic adenoviral mediated delivery of IL-4
43. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws
44. Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model
45. Studies on the contribution of c-fos/AP- 1 to arthritic joint destruction
46. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy
47. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint
48. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13
49. Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13
50. Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA)
51. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis
52. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy
53. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis
54. Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis
55. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor
56. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model
57. Targeting rare populations of murine antigen-specific T lymphocytes by retroviral transduction for potential application in gene therapy for autoimmune disease
58. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta
59. Gene transfer to synoviocytes: Prospects for gene treatment of arthritis
60. Getting genes into human synovium
61. Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: Implications for arthritis gene therapy
62. Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice
63. Intra-articular IL-4 gene therapy in arthritis: Anti-inflammatory effect and enhanced th2 activity
64. Adenoviral-mediated gene transfer to rabbit synovium in vivo
65. Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium
66. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction
67. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis
68. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo
69. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects
70. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model
71. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis
72. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist
73. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis
74. Gene transfer to synovial cells by intra-articular administration of plasmid DNA
75. Naked DNA as a gene delivery vehicle in inflammatory diseases
76. In vivo direct gene transfer into articular cartilage by intraarticular injection mediated by HVJ (Sendai virus) and liposomes
77. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees
78. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts
79. Lessons learned from gene transfer approaches
80. Adenoviral mediated gene transfer of IGF-1 stimulates cartilage synthesis in rabbit joints
81. Increased matrix synthesis following adenoviral transfer of a transforming growth factor beta-1 gene into articular chondrocytes
82. Genetic enhancement of matrix synthesis by articular chondrocytes: Comparison of different growth factors in the presence and absence of interleukin-1
83. Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis
84. Intraarticular expression of the IL-1Ra gene following direct delivery with an adeno-associated virus vector
85. Molecular lysis of synovial lining cells by in vivo herpes simplex virus-thymidine kinase gene transfer
86. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys
87. Adenoviral mediated delivery of FAS ligand to rheumatoid synovium results in extensive apoptosis in the synovial lining
88. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer
89. Novel gene therapy for rheumatoid arthritis by FADD gene transfer: Induction of apoptosis of rheumatoid synoviocytes but not chondrocytes
90. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer
91. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium
92. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy
93. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA
94. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee
95. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective
96. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model
97. Evidence for neurogenic transmission inducing degenerative cartilage damage distant from local inflammation
98. Transfer and expression of the viral IL-10 gene in vivo induces a suppressor population of antigen presenting cells which adoptively transfer suppression to soluble antigens; evidence for involvement of dendritic cells and macrophages
99. In vivo gene therapy of an equine model of osteoarthritis
100. Regulated gene expression systems
101. A two-component expression system that responds to inflammatory stimuli in vivo
102. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis
103. Gene therapy for rheumatoid arthritis: Clinical studies